Nature Medicine, Published online: 11 August 2026; doi:10.1038/s41591-026-04537-w
Circulating tumor DNA analyses in 44 patients with pancreatic cancer receiving the RAS(ON) multi-selective inhibitor daraxonrasib as part of a phase 1/2 trial, and preclinical translational modeling approaches, identify mechanisms of acquired resistance to monotherapy and inform potential combination strategies to overcome resistance.
